JAMA Perspective Flags Irreversibility Risks in Scaling Gene Editing to Common Conditions Like Hypercholesterolemia

The perspective contrasts rare-disease successes such as Zolgensma for SMA and Casgevy for sickle cell with proposed applications to the 39 million US adults on lipid-lowering therapy. Current viral-vector and base-editing platforms achieve durable hepatic editing in non-human primates yet trigger anti-capsid immunity that precludes redosing, while off-target indels and clonal hematopoiesis signals remain incompletely quantified in large populations. Murthy and Smith note that statins permit titration and withdrawal; a permanent edit does not. They highlight that even a 50 % sustained LDL reduction could shift primary-prevention paradigms only if long-term safety data exceed the 10-year horizon already available for PCSK9 monoclonal antibodies. Next steps include FDA-mandated registries tracking cardiovascular events and malignancy incidence for at least 15 years post-treatment, plus development of reversible epigenetic editors or transient mRNA approaches that preserve optionality for the far larger at-risk population.